Abstract Details

Title Frequency and predictors of obstructive sleep apnea in a cognitively impaired clinic population

Topic Sleep

Presentation(s) S9 - Sleep: Highlight Presentations on RBD (2:24 PM-2:32 PM)

Poster/Presentation
Number 003

Objective (1) To assess the frequency and predictors of obstructive sleep apnea (OSA) in patients with cognitive impairment due to a neurodegenerative and/or vascular etiology in a tertiary care clinic population. (2) To assess the correlation of OSA with cognitive impairment and actigraphy-derived sleep quality.

Background

OSA is a common sleep disorder which results in repeated pauses in breathing during sleep and is associated with an increased risk of developing cognitive impairment. OSA is prevalent in the general population and its prevalence increases in patients who have dementia. However, the frequency and predictors of OSA have not been well-established in Alzheimer’s disease and other related conditions such as vascular dementia.

Design/Methods Patients with cognitive impairment primarily attributable to an underlying neurodegenerative and/or vascular etiology were enrolled. Patients completed various assessments and questionnaires related to sleep, cognition and mood. A home sleep apnea test (HSAT) was used to assess patients for OSA.

Results Sixty-seven patients had complete HSAT recordings (i.e. ≥4 hours of analyzable HSAT data). Patients had a mean age (±SD) of 72.8 (±10.1) years, 44.8% were male and the mean (±SD) body mass index was 25.6 (±5.5). OSA was detected in 52.2% of the study population. Logistic regression demonstrated that OSA was significantly associated with a lower Montreal Cognitive Assessment score (OR: 0.40, p=0.048). Severity of OSA was correlated with degree of cognitive impairment and actigraphy-derived sleep variables (lower total sleep time, greater sleep onset latency, lower sleep efficiency, and greater awakenings)

Conclusions Our study demonstrated that OSA is common in patients with cognitive impairment and is correlated with lower cognition and poorer sleep quality. Future research should examine OSA prevalence in larger cohorts and assess predictors in specific neurodegenerative and/or vascular etiologies for cognitive impairment.

Authors/Disclosures
David R. Colelli, MSc (Sunnybrook Health Science Centre) PRESENTER	Mr. Colelli has nothing to disclose.
Sandra E. Black, MD, FAAN (Sunnybrook Health Science Center)	Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Hoffmann-La Roche. Dr. Black has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffmann-La Roche. Dr. Black has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai Limited . Dr. Black has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Black has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Black has received research support from Hoffmann-La Roche. The institution of Dr. Black has received research support from Biogen. The institution of Dr. Black has received research support from GE Healthcare. The institution of Dr. Black has received research support from Eli Lilly. The institution of Dr. Black has received research support from Genentech. The institution of Dr. Black has received research support from NovoNordisk. The institution of Dr. Black has received research support from UCB Biopharma. The institution of Dr. Black has received research support from Alkahest Inc. The institution of Dr. Black has received research support from University of Southern California - AHEAD 3-45 Study.
Mario Masellis, MD (Sunnybrook Health Sciences Centre)	Dr. Masellis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arkuda Therapeutics. Dr. Masellis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Masellis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alector. Dr. Masellis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Wave Life Sciences. The institution of Dr. Masellis has received research support from Canadian Institutes of Health Research. The institution of Dr. Masellis has received research support from Ontario Brain Institute. The institution of Dr. Masellis has received research support from Weston Brain Institute. The institution of Dr. Masellis has received research support from Washington University. The institution of Dr. Masellis has received research support from Alector. Dr. Masellis has received publishing royalties from a publication relating to health care.
	No disclosure on file
Andrew Lim, MD (Univ Toronto / Lim and Hew Med Prof Corp)	Dr. Lim has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai Canada.
Mark I. Boulos, MD, FRCPC, CSCN(EEG), MSc (Sunnybrook Health Sciences Centre)	Dr. Boulos has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precision AQ. Dr. Boulos has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sleep Medicine (journal). The institution of Dr. Boulos has received research support from Canadian Institutes of Health Research. The institution of Dr. Boulos has received research support from Slamen-Fast New Initiatives in Neurology Award. The institution of Dr. Boulos has received research support from Green Mountain . The institution of Dr. Boulos has received research support from RLS Foundation. The institution of Dr. Boulos has received research support from Temerty Centre for AI Research and ��ɫ�� in Medicine (T-CAIREM). The institution of Dr. Boulos has received research support from Heart & Stroke Foundation of Canada. The institution of Dr. Boulos has received research support from Alternative Funding Plan from the Academic Health Sciences Centres of Ontario. The institution of Dr. Boulos has received research support from StrokeCog. The institution of Dr. Boulos has received research support from McLaughlin Centre for Molecular Medicine . Dr. Boulos has received personal compensation in the range of $5,000-$9,999 for serving as a Speaker with Jazz Pharmaceuticals.

��ɫ����

��ɫ����

��ɫ��

��ɫ��